VRDN Stock: Price, Earnings History and SEC Filings
Viridian Therapeutics, Inc. (VRDN) last traded at $24.67, down 0.52% on the latest session and up 19.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.05 against an analyst estimate of $-0.97, a miss of 8.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VRDN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-1.05 | $-0.97 | -8.25% |
| Mar 2026 | May 5, 2026 | $-0.90 | $-1.06 | +15.09% |
| Dec 2025 | Feb 26, 2026 | $-1.08 | $-0.90 | -20.00% |
| Sep 2025 | Nov 5, 2025 | $-0.34 | $-0.82 | +58.54% |
VRDN beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How VRDN reacts to earnings
Across its last 8 earnings releases, VRDN moved 8.8% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +6.83% |
| 2026-05-05 | Before open | +33.36% |
| 2026-02-26 | Before open | +1.90% |
| 2025-11-05 | Before open | +8.29% |
| 2025-10-21 | After close | -8.83% |
| 2025-08-06 | Before open | -1.38% |
| 2025-05-06 | Before open | -8.31% |
| 2025-02-27 | Before open | -1.55% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
VRDN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $71M | -$343M | -$277M | -483.6% | – |
| 2024 | $302000 | -$270M | -$233M | -89387.1% | – |
| 2023 | $314000 | -$238M | -$185M | -75711.5% | $-5.31 |
| 2022 | $2M | -$130M | -$95M | -7329.2% | $-4.05 |
| 2021 | $3M | -$79M | -$55M | -2680.2% | $-6.66 |
| 2020 | $1M | -$111M | -$30M | -10544.3% | $-31.13 |
| 2019 | $4M | -$42M | -$36M | -938.6% | – |
| 2018 | $8M | -$33M | -$27M | -390.0% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for VRDN
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 29, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · Jun 3, 2026Shareholder vote
- 8-K · May 28, 2026Agreement terminated
- 8-K · May 26, 2026Material agreement
- 8-K · May 11, 2026Material agreement, New financial obligation, Other events
- 424B5 · May 8, 2026
- 424B5 · May 8, 2026
- 424B5 · May 6, 2026
Insider filing activity
VRDN insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
VRDN news
- How FDA Approval Will Impact Viridian Therapeutics StockOct 27, 2026 · finance.yahoo.com
- Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026Oct 20, 2026 · finance.yahoo.com
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (VRDN) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.